Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3 (CIN3)

A Single Center, Open-label, Dose-escalating, Phase Ι Study to Evaluate the Safety of GX-188E Administered by Electroporation (EP) in DNA-based Therapeutic Vaccine for Patients With Cervical Intraepithelial Neoplasia Grade 3 (CIN 3)

This study is to determine maximum tolerable dose (MTD) of GX 188E by defining the safety profile the safety and maximum tolerated dose of GX-188E administered by electroporation in Cervical Intraepithelial Neoplasia grade 3 (CIN 3) patients.

Study Overview

• Status: Completed
• Conditions: Cervical Intraepithelial Neoplasia 3
• Intervention / Treatment: Genetic: GX-188E administered by electroporation

Detailed Description

This study is an open-label, dose-escalation, single-center, phase I study to evaluate the safety of GX-188E, a DNA-based therapeutic vaccine, administered by electroporation (EP) in patients with HPV-16 or HPV-18 associated cervical intraepithelial neoplasia grade 3 (CIN 3).

Each subject eligible to participate in the trial is given a subject number, which is assigned sequentially in ascending order, then allocated to only a single dose level of the drug. Three subjects are allocated at each dose level starting with 1mg whereby the dose is escalated in sequential subjects in ascending numerical order of subject ID.

Each subject visit the site three times for administration during the study and is given an intramuscular injection of GX-188E at a dose of 1mg, 2mg or 4mg by electroporation at each visit

The subjects conduct the follow-up visits twice, which are 8 weeks and 24 weeks after the third injection of GX-188E respectively.

• Study Type: Interventional
• Enrollment (Actual): 9
• Phase: Phase 1

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of
    • Cheil General Hospital & Women's Healthcare Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 50 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Female aged between 20 and 50(inclusive).
• Those who promised not to get pregnant from initiation to the first follow-up visit
• Who has diagnosed with Cervical Intraepithelial Neoplasia 3 by histopathologic examination and HPV type 16 or 18 detected
• Those who signed a voluntary written informed consent form for study participation.

Exclusion Criteria:

• Pregnant or lactating women.
• Administration of immunosuppressant or immunomodulator within 6 months prior to the enrollment
• Concomitant medication of any corticosteroid agents within 4 weeks prior to vaccination with the test drug
• Prior immunotherapy against HPV
• Administration of any blood products within 3 months prior to the screening visit
• Administration of any vaccine within 4 weeks prior to the screening visit (ex. Hepatitis A vaccine, Hepatitis B vaccine, Influenza vaccine, Td etc.)
• Positive serum test results for hepatitis C virus, hepatitis B virus surface antigen(HBsAg), or HIV
• Prior participation in any clinical trial within 30 days prior to the screening visit
• Patients predisposed to inflammatory reaction due to use of medical devices such as electroporation within 30 days of screening visit
• Past history of epilepsy or convulsion within 2 years prior to the screening visit
• At the discretion of the investigator, the skin condition covering deltoid muscles, within 2cm of the intended sites of injection, is not suitable for injection due to infection, ulcer, edema, tattoo, scar, injury etc.
• The thickness of skin fold covering deltoid muscles, intended injection sites, >40mm
• Any orthopedic artificial implant around the intended sites of electroporation (deltoid muscles)
• Any history of severe adverse drug events or severe allergic diseases
• Sinus bradycardia whose resting heart rate < 50beats/min.
• Pre-excitation syndrome such as Wolff-Parkinson-White syndrome
• Artificial implants or metallic implants
• Abnormal electrocardiography (ECG) including arrhythmia
• Any other ineligible condition at the discretion of the investigator that would be ineligible to participate the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1mg of GX-188E by electroporation	Genetic: GX-188E administered by electroporation; Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.; Other Names: Trigrid™ Delivery System
Experimental: 2mg of GX-188E by electroporation	Genetic: GX-188E administered by electroporation; Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.; Other Names: Trigrid™ Delivery System
Experimental: 4mg of GX-188E by electroporation	Genetic: GX-188E administered by electroporation; Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.; Other Names: Trigrid™ Delivery System

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Determination of maximum MTD by defining the safety profile of GX-188E	It would be determined based on the rate and severity grade of events or abnormalities through evaluating systemic or local adverse events, clinical laboratory test results, vital signs and so on.	From baseline to end of study

Secondary Outcome Measures

Outcome Measure	Time Frame
The expression levels of GX-188E in blood	At week -2, week 2, week 12 ,week 20 and week 36
Immunologic reactogenicity by measuring HPV E6 and E7 specific T cell response (IFN-γ ELISPOT)	At week -2, week 2, week 12 ,week 20 and week 36
The changes of the involved lesions and HPV infection status	Baseline, week 12 ,week 20 and week 36

Collaborators and Investigators

• Sponsor: Genexine, Inc.
• Investigators: Principal Investigator: Tae Jin Kim, Cheil General Hospital & Women's Healthcare Center

Study record dates

Study Major Dates

• Study Start: November 1, 2012
• Primary Completion (Actual): February 1, 2014
• Study Completion (Actual): February 1, 2014

Study Registration Dates

• First Submitted: July 3, 2012
• First Submitted That Met QC Criteria: July 5, 2012
• First Posted (Estimate): July 6, 2012

Study Record Updates

• Last Update Posted (Estimate): February 17, 2014
• Last Update Submitted That Met QC Criteria: February 14, 2014
• Last Verified: February 1, 2014

More Information

Terms related to this study

• Keywords: Safety; Cervical Intraepithelial Neoplasia; Phase 1; Adult; Dose Finding; 3+3 design
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms; Carcinoma in Situ; Cervical Intraepithelial Neoplasia
• Other Study ID Numbers: GX-188E-SN